Cambridge Healthtech Institute’s Inaugural
Part of the Tenth Annual PEGS: the essential protein engineering summit
May 8-9, 2014| Seaport World Trade Center | Boston, MA
By 2018, the global Peptide Therapeutics market is expected to reach over $25 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include high-throughput approaches. Conjugation technologies are also contributing to the growth of peptide therapeutics, and leading to innovative approaches to designing safe and effective therapies.
This meeting will explore the burgeoning world of Peptide Therapeutics and how peptides are being engineered to penetrate tumors and conquer unmet medical needs. Improving peptide properties, such as stability and half-life, will also be discussed along with innovating routes of administration. Case studies will be presented that illustrate the progress made in developing efficacious peptide therapeutics, while leaders in the field point the way to the future for these promising drugs.
OPENING KEYNOTE PRESENTATION:
Pharmaceutical Protein & Peptide Engineering: From Once Daily to Once Weekly GLP-1 Dosing
Jesper Lau, Ph.D., Vice President, Diabetes Protein & Peptide Chemistry, Novo Nordisk A/S
Highly Constrained Bicyclic Peptides (Bicycles): A Novel Class of Therapeutic
Christophe Bonny, Ph.D., CSO, Bicycle Therapeutics, Ltd.
Structure-Based Discovery of ATSP-7041, a Dual MDM2 and MDMX Targeting Stapled Helical Peptide Exhibiting Potency in vitro and in vivo Efficacy in Xenograft Models of Human Cancer
Yong S. Chang, Ph.D., Vice President, Biology and Translational Research, Aileron Therapeutics, Inc.
A General Method for Making Peptide Therapeutics Resistant to Serine Protease Degradation; Application to Dipeptidyl Peptidase IV Substrates
William Bachovchin, Ph.D., Professor, Developmental, Molecular & Chemical Biology, Sackler School of Graduate and Biomedical Sciences, Tufts University
PK Modulation of Haptenylated Peptides via Non-Covalent Antibody Complexation
Ulrich Brinkmann, Ph.D., Scientific Director, Pharma Research and Early Development, Roche
AlbudAb: A Versatile Serum Half-Life Extension Platform for Peptides
Chris Herring, Ph.D., Head, Protein Sciences, GlaxoSmithKline
Novel ApoA-I Mimetic Peptides for the Treatment of Cardiovascular Disease
Alan T. Remaley, M.D., Ph.D., Section Chief, Lipoprotein Metabolism Laboratory, National Institutes of Health (NIH)
Using Engineered Peptides to Deliver Peptide/Protein Therapeutics into Cells
Jean-Philippe Pellois, Ph.D., Associate Professor, Biochemistry and Biophysics, Texas A&M University
Peptide Delivery of a Therapeutic Nucleic Acid Analog
Hong Moulton, Ph.D., Associate Professor, Senior Researcher, Biomedical Sciences, Oregon State University
Engineering Scorpion Venom Peptides to Generate High Potent and Selective Therapeutics Targeting the Potassium Channel Kv1.3
ChiChi Huang, Ph.D., Scientific Director, Antibody Drug Discovery, Janssen R&D, LLC
Apolipoprotein E Derived ABCA1 Agonists for the Treatment of Cardiovascular Disease, Diabetes and Alzheimer’s Disease
Jan Johansson, Ph.D., CEO & President, Artery Therapeutics, Inc.
Peptides with a Defined Structure: Half-Life Extended Affibody Molecules with High Potency and Stability Allowing for Alternative Delivery Routes
Fredrik Frejd, Ph.D., CSO & Vice President, R&D, Biopharma, Affibody AB
Inactivating HIV-1 Using Peptide Triazoles and Their Nanoparticle Conjugates
Irwin Chaiken, Ph.D., Professor, Biochemistry and Molecular Biology Drexel University College of Medicine
Characterization of a New Brain-Penetrant Angiopep2-Neurotensin Derivative (ANG2002) with Antinociceptive Properties
Philippe Sarret, Ph.D., Professor, Physiology and Biophysics, University of Sherbrooke
"The meeting was excellent: very well organized, great choice of presenters from academia, government and industry.
Principal Investigator, Senior Staff Fellow, Hematology, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA)
I have set two collaborative studies during the meeting as a result of the talks and interesting topics."